Steinmetz JD, Seeher KM, Schiess N, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344–81.

Article  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.

Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(8):1286–99.

Article  PubMed  PubMed Central  Google Scholar 

Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96–107.

Article  PubMed  Google Scholar 

Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.

Article  PubMed  Google Scholar 

Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–55.

Article  PubMed  Google Scholar 

Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–74.

Article  PubMed  CAS  Google Scholar 

Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023. https://doi.org/10.1177/03331024231159366.

Article  PubMed  Google Scholar 

Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–32.

Article  PubMed  Google Scholar 

Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026–44.

Article  PubMed  Google Scholar 

Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837–50.

Article  PubMed  Google Scholar 

Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2021;42(4–5):326–34.

PubMed  PubMed Central  Google Scholar 

Guerzoni S, Baraldi C, Pensato U, et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. 2022;43(6):3823–30.

Article  PubMed  Google Scholar 

Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs). J Headache Pain. 2019. https://doi.org/10.1186/s10194-019-1009-9.

Article  PubMed  PubMed Central  Google Scholar 

Diener HC. Prophylaxe Der Migräne Mit Monoklonalen Antikörpern Gegen CGRP Oder Den CGRP-Rezeptor, Ergänzung Der S1-Leitlinie Therapie Der Migräneattacke Und Prophylaxe Der Migräne: Zusammenfassung Der Empfehlungen Der DGN Und DMKG. DGNeurol. 2020;3:124–8.

Article  Google Scholar 

Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019. https://doi.org/10.1186/s10194-018-0955-y.

Article  PubMed  PubMed Central  Google Scholar 

Alsaadi T, Kayed DM, Al-Madani A, et al. Consensus-based recommendations on the use of CGRP-based therapies for migraine prevention in the UAE. Neurol Ther. 2023;12(6):1845–65.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie J, Bossuyt P, The PRISMA, et al. Statement: an updated guideline for reporting systematic reviews. Cent Open Sci. 2020. https://doi.org/10.3122/osf.io/v7gm2.

Article  Google Scholar 

Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Training. https://training.cochrane.org/handbook/current. Accessed 19 Dec 2024.

CombineMeanSD. https://www.statstodo.com/CombineMeansSDs.php. Accessed 19 Dec 2024.

automeris.io: computer vision assisted data extraction from charts using WebPlotDigitizer. https://automeris.io/wpd/. Accessed 19 Dec 2024.

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https://doi.org/10.1136/bmj.i4919.

Article  PubMed  PubMed Central  Google Scholar 

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020;12(1):55–61.

Article  PubMed  Google Scholar 

Gantenbein AR, Agosti R, Gobbi C, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment—a real-life cohort study. Cephalalgia. 2021;41(11–12):1181–6.

Article  PubMed  PubMed Central  Google Scholar 

Gantenbein AR, Bonvin C, Kamm CP, et al. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol. 2024;271(8):5402–10.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nsaka M, Scheffler A, Wurthmann S, et al. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav. 2022. https://doi.org/10.1002/brb3.2662.

Article  PubMed  PubMed Central  Google Scholar 

Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019. https://doi.org/10.1186/s10194-019-1018-8.

Article  PubMed  PubMed Central  Google Scholar 

Takeshima T, Doi H, Ooba S, Tanji Y, Ozeki A, Komori M. Clinical evaluation after discontinuation of galcanezumab in Japanese patients with episodic and chronic migraine: analysis of a randomized, placebo-controlled trial and open-label extension study. Neurol Ther. 2024;13(3):697–714.

Article  PubMed  PubMed Central  Google Scholar 

Tereshko Y, Dal Bello S, Pez S, et al. Comparative study of the efficacy of anti-CGRP mAbs on migraineurs: analysis of the first year of therapy, 1-month suspension period, and reprisal. J Clin Med. 2023;12(23):7329.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vernieri F, Brunelli N, Guerzoni S, et al. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study. J Neurol. 2023;270(11):5436–48. https://doi.org/10.1007/s00415-023-11872-2.

Article  PubMed  CAS  Google Scholar 

di Cola FS, Caratozzolo S, Venturelli E, et al. Erenumab discontinuation after 12-month treatment. Neurol Clin Pract. 2021. https://doi.org/10.1212/cpj.0000000000001112.

Article  Google Scholar 

Cho S, Kim B. Long-term outcome after discontinuation of CGRP-targeting therapy for migraine. Curr Pain Headache Rep. 2024;28(8):743–51. https://doi.org/10.1007/s11916-024-01259-x.

Article  PubMed  Google Scholar 

AIPS. Einzelabfrage. https://www.swissmedicinfo.ch/ViewMonographie. Accessed 19 Dec 2024.

Agenzia Italiana del Farmaco. Aimovig (erenumab) Indicazione rimborsata. https://www.aifa.gov.it/documents/20142/1220805/AIMOVIG_13821_INNOV._v.1.0.pdf. Accessed Nov 2018.

Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101.

Article  PubMed  PubMed Central